Introduction
Iron metabolism is a tightly regulated process. Haem iron and inorganic iron are absorbed at the apical membrane of the enterocyte and release to blood through its basolateral membrane by ferroportin 1. Iron storage at liver and macrophages is mostly in the form of ferritin. Iron transport from absorption and storage sites to the bone marrow is provided by transferrin, which makes iron available for incorporation into haemoglobin (Hb) (Fig. 1 ) [1] .
Under physiological conditions, there is a balance between iron absorption, iron transport and iron storage in the human body. However, iron deficiency and iron-deficiency anaemia (IDA) are common conditions among medical, surgical and critically ill patients, and result from the interplay of three distinct risk factors: increased iron requirements, limited external supply and increased blood loss (Table 1) [2] . Iron deficiency can be either absolute or functional. In absolute iron deficiency, the iron stores are depleted; in functional iron deficiency (FID), iron stores, although replete, cannot be mobilized as fast as necessary from the macrophages of the reticuloendothelial system (RES) to the bone marrow.
Functional iron deficiency occurs in anaemia of inflammatory diseases because iron is trapped in the RES as a result of increased secretion of hepcidin, a hormone that controls ferroportin activity in releasing iron from cells ( Fig. 1) [1, 2] . FID may also occur in response to the therapeutic use of erythropoiesis-stimulating agents (ESA), such as epoetin or darbopoetin, which place a significant demand on iron stores that may surpass the iron-release capacity of the RES [3] . Thus, laboratory tests for investigating iron deficiency fall into two categories: measurements providing evidence of iron depletion in the body and measurements reflecting iron deficient red cell production (Table 2 ) [4] . The appropriate combination of these laboratory tests will help to establish a correct diagnosis of anaemia and iron-deficiency status [5] .
Allogeneic blood transfusion (ABT) is commonly used to rapidly and effectively restore the Hb levels, avoiding at least in theory the deleterious effects of severe anaemia, especially when acutely developed or in elderly patients whose cardiorespiratory compensatory mechanisms have a limited capacity of response. However, although increasingly safer, ABT can never be risk free, reflecting as it does the current state of health of society, just as new illnesses and infections will influence the overall health picture, their impact on blood safety cannot be predicted [6] . Thus, concerns about adverse effects of ABT have prompted the review of transfusion practice, and the search for a safer and more biologically rational treatment of anaemia (i.e. pharmacological treatment), in order to diminish ABT-related risks as well as to hasten recovery of patent's functional capacity. As for IDA (e.g. poor intake, chronic blood losses), iron absorption is increased and, provided there is no pathology of the gastrointestinal tract, oral iron administration usually leads to correction of the anaemia. In contrast, in anaemia of chronic inflammation (e.g. rheumatoid arthritis, Crohn's disease, chronic renal or heart failure, cancer), as well as in that associated with acute inflammation (e.g. trauma, surgery, etc.), especially is associated with iron deficiency, the utility of oral iron administration may be limited, because absorption is down-regulated, and the small amount of iron absorbed is directed to the RES, where it is sequestered. Hepdicin, a hepatic acute-phase protein, plays a major role in both processes through its effects on ferroportin expression and activity (Fig. 1) [1, 5] . Intravenous iron may be a more effective mode of administration in these situations, as well as in cases of intolerance or contraindication to oral iron, treatment with ESAs, short time to surgery, or severe anaemia. In this review we will focus on the efficacy and safety of intravenous iron administration as an alternative/adjunct to ABT for the treatment of anaemic patients in different clinical contexts.
Intravenous iron agents

Structure, biochemistry and pharmacokinetic properties
All intravenous iron agents are colloids with spheroidal iron-carbohydrate nanoparticles. Each particle consists of an iron-oxyhydroxide core [Fe (III)] and a carbohydrate shell that stabilizes the iron-oxyhydroxide core. Three different products are principally used in clinical practice: iron dextran (73-265 kDa), iron gluconate (38 kDa) and iron sucrose (43 kDa) [7, 8] , and differences in core size and carbohydrate chemistry determine pharmacological and biological differences between the different agents, including clearance after injection, iron release in vitro , early evidence of iron bioactivity in vivo , and maximum tolerated dose and rate of infusion [9, 10] (Table 3) .
After intravenous injection, iron-carbohydrate agents mix with plasma, then enter the RES directly from the intravascular fluid compartment. Resident phagocytes of the liver, spleen and bone marrow remove iron agent from the circulating plasma. Within phagocytes, iron is released from the iron-carbohydrate compound into a low molecular weight iron pool. Low molecular weight iron either is incorporated by ferritin into intracellular iron stores or is released from the cell to be taken up by the extracellular iron-binding protein transferrin [11] . A small fraction, however, likely bypasses the intracellular steps and donates iron directly to transferrin in plasma (Table 3 ) [10] . Transferrin delivers iron to transferrin receptors on the surface of erythroid precursors, and the resulting internalization of the iron-transferrin-transferrin receptor complex supplies iron for Hb synthesis and maturation of the red cell [11] .
The precise cellular events by which iron-carbohydrate compounds are taken up by RES phagocytes and thereby cleared from plasma have not been elucidated, although it seems to be a saturable process and to depend on molecular weight [11] . In contrast, the rate of transfer of iron from RES into circulating red cells seems to depend on the severity of iron deficiency, the rate of erythropoiesis, or circulating factors that influence those disorders (e.g. hepcidin): it is more rapid and more complete in patients with iron deficiency that in patients with cancer or inflammation [11] . In addition, given the same iron loading dose, experimental animals show higher RES iron levels after iron dextran than after ferric gluconate and iron sucrose, suggesting that the rate of metabolism and utilization of intravenous iron may be lower for agents with higher molecular weights [11] .
Adverse side-effects
Allergic and anaphylactic reactions
The stability of the dextran complex allows administration of high single doses (so-called 'total dose therapy'). However, these iron complexes may cause well-know dextran-induced anaphylactic reactions that occur in some patients receiving iron dextran [12] . In contrast, iron gluconate is a labile type with fast degradation kinetics and has the potential for acute adverse reactions related to labile iron release. Non-transferrin bound labile iron may induce acute endothelial cell injury and a transient capillary leak syndrome (nausea, hypotension, tachycardia, chest pain, dyspnoea due to lung oedema, and bilateral oedema of the hands and feet) that should not be misread as anaphylaxis [9] . To avoid these side-effects, maximum recommended single dose is 125 mg; whereas the administration of total dose is not recommended. Finally, as for iron sucrose if the infusion speed is too fast (above 4 mg Fe 3 + /min) or the single total iron dose too high (above 7 mg Fe 3 + /kg), labile iron toxicity might occur [9] . Single doses of up to 300 mg are safe, and the maximal recommended dosage is 600 mg/week [12] . Overall, iron sucrose is currently considered as the safest intravenous iron preparation [7, 8] .
Although no serious life-threatening adverse events have been reported in the different studies reviewed in this paper, the number of patients included in these studies is not large enough to draw definitive conclusions regarding the safety of intravenous iron agents in different clinical settings. Therefore, this section will focus on adverse drug events (ADE) associated with parenteral iron in chronic kidney disease (CKD) patients.
According to data from the US Food and Drug Administration (FDA) on adjusted rate ADEs per 100 mg dose attributed to the provision of four formulations of intravenous iron during 2001-2003, including higher and lower molecular weight iron dextran, sodium ferric gluconate complex and iron sucrose, the total number of reported parenteral iron-related ADEs was 1141 among approximately 30 million doses administered (approximately 38 ADEs per million), with 11 deaths (seven iron dextran, three iron gluconate and iron sucrose) [13] . Relative to lower molecular weight iron dextran, total and life-threatening ADEs were significantly more frequent among recipients of higher molecular weight iron dextran and significantly less frequent among recipients of sodium ferric gluconate complex and iron sucrose. The absolute rates of life-threatening ADEs were 0·6, 0·9, 3·3 and 11·3 per 10 6 doses for iron sucrose, sodium ferric gluconate complex, lower molecular weight iron dextran and higher molecular weight iron dextran, respectively, whereas absolute rates of death were 0·11, 0·25, 0·75 and 0·78 per 10 6 doses, respectively. Therefore, the rates of intravenous iron-related ADEs reported to the FDA are extremely low and lifethreatening and other ADEs appear to be lower with the use of non-dextran iron formulations [13] .
Infection and iron
Current information on the relationship between intravenous iron and infection, and between intravenous iron and oxidative stress deserves special consideration. Elemental iron is an essential growth factor for bacteria with many species expressing iron transport proteins that compete with transferrin, and it has long been suggested that patients with iron overload are at increased risk of infection [14] . In contrast, in the peritoneal dialysis population, no increased risk of peritonitis was found in patients receiving with respect to those not receiving intravenous iron [15] . In addition, a study of 988 dialysis patients found that anaemia was associated with increased risk of bacteraemia (relative risk; RR 0·7 pre each 1 g/dl less of Hb) [16] . Nevertheless, despite this absence of definitive clinical data, it seems sensible to avoid intravenous iron administration in the setting of acute infection.
Oxidant damage and iron
Biologically active iron, which is released by all intravenous iron agents, also plays a role in inflammation, oxidant stress and the propensity for accelerated atherosclerosis. Persistent oxidative stress in CKD patients promoted inflammation and, in turn, atherogenesis, and increased cardiovascular morbidity and mortality. However, available evidence relating intravenous iron administration to atherogenesis is indirect, and there is little evidence that intravenous iron adversely affects survival in patients with dialysis-dependent CKD. Nevertheless, the evidence argues for caution, not complacency, in prescribing intravenous iron [9] .
Iron overload
If iron status is not followed closely, patients receiving intravenous iron may develop iron overload. In short, markers of risk, stores and efficacy all prompt a single conclusion: intravenous iron is associated with evidence of increased risk and excessive tissue iron stores in patients with a serum ferritin > 600 ng/ml and a lack of therapeutic efficacy in the patient with a serum ferritin > 500 ng/ml. The evidence supports withholding intravenous iron in patients with pretreatment ferritin values > 500 ng/ml [9] . However, it should be emphasized that in CKD patients, administered iron accumulates preferentially in the macrophages of the RES, including the Kupffer cells of the liver. Therefore, the deleterious effects of the overload are of lesser significance compared to idiopathic haemochromatosis where iron accumulation occurs primarily in parenchymal cells [12] .
Intravenous iron therapy in non-surgical patients
Pregnancy and postpartum
Anaemia due to iron deficiency or iron loss is a common condition both during pregnancy and postpartum [17] . Bayoumeu et al . [18] in a random, prospective, open study with individual benefit compared intravenous iron sucrose vs. oral iron sulphate in 50 patients with haemoglobin levels between 8 and 10 g/dl and a ferritin value of < 50 ng/ml. On day 30, no differences in Hb increase were observed between groups, though ferritin levels were higher in the intravenous group both on day 30 and at delivery. In contrast, Al et al . [19] in a randomized study open-label study in 90 patients with similar Hb (8-10·5 g/dl) but lower ferritin value ( < 13 ng/ml) found iron sucrose to increase Hb and restore iron stores faster than oral iron during the first month of treatment. Similar results were previously reported in a nonrandomized prospective study where 111 pregnant women with IDA (ferritin < 20 ng/ml) were sequentially assigned to intravenous or oral iron [20] . Overall, between 1992 and 2005, more than 500 pregnant women with IDA were treated at the Zurich Obstetrics Clinic (mean iron sucrose total dose, 1000 mg) and no serious adverse events were witnessed (mean increase in Hb, 2 g/dl) [17] . From the results of these studies, it might be concluded that iron sucrose appears to be a treatment without serious side-effects indicated in correction of pregnancy anaemia and iron stores depletion. Regarding the treatment of postpartum anaemia, Breymann et al . [21] randomized 40 patients with postpartum anaemia (Hb = 86 ± 11 g/l) to receive iron sucrose or oral iron alone, daily for 4 days beginning 48-72 h postpartum, and found that both regimens were of equal efficacy in both rate and degree of Hb recovery in the postpartum period. In contrast, in two more recent studies, intravenous iron sucrose was shown to be superior to oral iron for treating anaemic puerperae [22, 23] . However, Bhandal et al . [22] gave iron only to those patients with proven iron deficiency as a cause of their anaemia, whereas Breyman et al . [21] excluded those with prepartum anaemia. These results suggest that oral and intravenous iron appear to be largely equivalent except perhaps in particular circumstances, whereas additional treatment with rHuEPO should be reserved for those patients with profound postpartum inflammation (e.g. anaemic patients after Caesarean section) [24] .
Inflammatory bowel disease
Approximately, one-third of inflammatory bowel disease (IBD) patients suffer from recurrent anaemia; a condition having a significant impact on the quality of life of affected patients. Both iron deficiency (due to blood loss in intestine that cannot be matched by duodenal iron absorption, creating a negative iron balance) and anaemia of chronic disease (due to the inflammatory nature of the disease) contribute most to the development of anaemia in IBD, whereas cobalamin or folate deficiency and various other causes of anaemia such as haemolysis occur infrequently [25] .
The efficacy of oral iron therapy in these patients may be hindered by some IBD-specific factors, such as gastrointestinal side-effects of oral ferrous iron (due to the release of activated hydroxyl radicals) or reduced absorption of iron due to inflammation [26] . These limitations of oral iron therapy in IBD patients mean that parenteral routes of iron administration should be considered. In this regard, an observational study in IBD patients with poor response or intolerance to oral iron, the administration of iron sucrose (200 mg once or twice per week to reach total iron deficiency) resulted in a positive response (Hb increment ≥ 2 g/dl or correction of anaemia) in 60% of patients within 8 weeks and in 90% of patients within 12 weeks [27] . However, a randomized, controlled, open-label, multicentre trial performed in 46 patients with anaemia and transferrin saturation ≤ 20% and/or serum ferritin concentrations ≤ 20 μ g/l found no differences in Hb increment within 6 weeks between patients receiving iron sucrose and those receiving iron sulphate, but resulted in building up iron stores (ferritin 200 ng/ml approximately after 6 weeks) [28] . In addition, intractable gastrointestinal adverse events caused permanent study drug discontinuation in five patients (20·8%) receiving iron sulphate, whereas only one patient (4·5%) had to be withdrawn because of side-effects due to iron sucrose [28] . In another randomized study, oral ferrous fumarate, but not intravenous iron sucrose, increased clinical disease activity in IBD patients, whereas intravenous iron sucrose increased intravascular oxidative stress [29] . Thus, although being equal in short-term efficacy and overall tolerability, these results suggest a better gastrointestinal tolerability for iron sucrose. However, further research is needed to ascertain what is the appropriate timing to start treatment, the target Hb and ferritin levels to reach, or how intravenous iron may affect IBD clinical time course.
Congestive heart failure
There is increasing evidence that anaemia is one of the most relevant comorbid conditions associated with chronic heart failure (CHF), not only because it is common but also because it is a marker of greater impairment in functional capacity and an independent predictor of mortality and hospitalization among CHF patients [30] . The aetiology of anaemia in CHF patients is probably multifactorial, and it has been suggested the existence of a vicious circle between heart failure, anaemia and CKD, the so-called cardio-renal-anaemia syndrome [30] . A recent trial has shown that in anaemic CHF patients, correction of anaemia with rHuEPO and oral iron (increase in Hb from 10·4 ± 0·6 to 12·4 ± 0·8 g/dl; P < 0·01) leads to improvement in New York Heart Association status, measured exercise endurance, oxygen use during exercise, renal function and plasma B-type natriuretic peptide levels, and reduces the need for hospitalization [31] . However, both iron deficiency and FID may also play a role in the cardio-renal-anaemia syndrome. In this regard, Bolger et al . [32] found that iron sucrose administration to increase Hb levels (11·2 ± 0·7 vs. 12·6 ± 1·2; P < 0·001) reduces symptoms and improves exercise capacity in anaemic patients with CHF. In addition, there were no adverse events relating to drug administration or during follow-up. Further randomized trials, such as the iron in heart failure (IRON-HF) [33] , would answer the questions of which is the best Hb cut-off point to start treatment, what would be the best target Hb, which patients might benefit for intravenous iron alone, or when intravenous iron should be supplemented rHuEPO.
Chronic kidney disease
Nowadays, the administration of ESAs with iron supplements, but not ABT, is the standard therapy for the anaemia of CKD, although some patients are still being transfused. On the other hand, the effects of intravenous iron alone in partially correcting this anaemia were long ago reported. More recently, in anaemic non-dialysed CKD patients, the haematocrit response was more rapid in patients receiving intravenous iron in combination with low-dose rHuEPO, but 50% of patients with iron alone showed an increase in haematocrit greater than 3%. In addition, 29% of these patients reached the target haematocrit (35%) compared with 40% of those receiving the combination therapy [34] . Another two studies show that administration of intravenous iron to CKD patients significantly increased the haematocrit, with 35-40% reaching target haematocrit, in the absence of rHuEPO administration [35, 36] . Thus, it is clear that intravenous iron alone can achieve some correction of anaemia in CKD, possibly sufficient to avoid ABT, but many patients will also require ESAs supplementation to attained target Hb level.
Anaemia of cancer
Patients with cancer may have anaemia with iron deficiency or FID as a result of their disease or its treatment. These conditions can lead to an insufficient supply of iron for incorporation into erythrocytes during supportive care with ESAs for chemotherapy. Two recent studies of cancer patients receiving chemotherapy have shown that intravenous iron (iron dextran or ferric gluconate) increases the haematopoietic response to rHuEPO with respect to those receiving oral iron or no iron (70%, 40% and 35%, respectively) [37, 38] . The effects on Hb levels (2·4, 1·5 and 1·2 g/dl, respectively) and measures of iron metabolism were notably greater with intravenous iron formulations than with oral iron formulations. However, the FDA has recently issued an alert to provide new safety information for ESAs (darbepoetin alfa and epoetin alfa). Analyses of four new studies in patients with cancer found a higher chance of serious and life-threatening side-effects and/or death with the use of ESAs. Use of ESAs to achieve a target Hb of 12 g/dl or greater in cancer patients: (i) shortened the time to tumour progression in patients with advanced head and neck cancer receiving radiation therapy; (ii) shortened overall survival and increased deaths attributed to disease progression in patients with metastatic breast cancer receiving chemotherapy; and (iii) increased the risk of death in patients with active malignant disease not under treatment with chemotherapy or radiation therapy. These research studies were evaluating an unapproved dosing regimen, a patient population for which ESAs are not approved, or a new unapproved ESA [39] . Therefore, the increasingly uncertain role of ESAs in the treatment of cancer anaemia should be acknowledged.
Intravenous iron therapy in surgical patients
As for surgical patients, perioperative anaemia has been linked to increased postoperative morbidity and mortality and decreased quality of life [40] . Preoperative anaemia, which is one of the major predictive factors for ABT in surgeries with moderate to high perioperative blood loss [6] , may be present in one-third to one-half of them due to iron deficiency, chronic inflammation or both [3, 5] . Deficiencies of folic acid and/or vitamin B12 are also frequent, especially among elder population [3, 5] . Although oral administration should be the preferred mode of iron supplementation, this is, a time-consuming process and for some surgical patients with severe anaemia preoperative intravenous iron administration might be considered.
In contrast, postoperative anaemia is present in up to 90% of patients [40] . Perioperative blood loss is the main cause of postoperative anaemia, which may be aggravated by inflammation-induced blunted erythropoiesis, especially through decreased iron availability [41] . These alterations in iron metabolism also apply to critically ill and trauma patients [42] . Intravenous iron can allow up to a fivefold erythropoietic response to significant blood-loss anaemia in normal individuals [3] . However, patients with perioperative inflammatory anaemia most probably benefit from addition of rHuEPO to intravenous iron, as rHuEPO therapy increases iron mobilization from the RES into red blood cell precursors [3] .
Non-elective orthopaedic surgery
The administration of iron sucrose for treatment of acute anaemia in pertrochanteric (PHF) and subcapital (SHF) hip fracture patients was evaluated in three non-randomized studies, and no adverse reactions to iron administration were observed in any of them [43] [44] [45] . In the first two, there was a trend towards a lower transfusion rate (-13%), lower 30 -day mortality (-11%) and shorter hospital stay (-2 days) in patients (75 patients: 55 PHF, 20 SHF) receiving 200-300 mg iron sucrose preoperatively (significant for SHF patients) when compared to a historical control group (159 patients: 102 PHF, 57 SHF) [43, 44] . In a subsequent study, perioperative administration of 600 mg iron sucrose (plus 40 000 IU rHuEPO subcutaneously, if Hb < 13 g/dl upon admission) ( n = 83), together with a restrictive transfusion protocol (transfusion trigger: Hb < 8 g/dl and/or symptoms of acute anaemia), also resulted in a reduction of the percentage of transfused patients (24% vs. 71%, respectively; P < 0·05) when compared to a parallel control group from another surgical unit in the same institution (n = 41) [45] . In addition, there was a trend towards reduced 30-day mortality (7% vs. 15%, respectively) [45] .
Elective orthopaedic surgery
In a recent observational study, 27 consecutive patients scheduled to undergo major orthopedic surgery were given preoperative intravenous iron infusions (600-1200 mg over 2-3 weeks) because of intolerance to oral iron administration, poor intestinal absorption, chronic inflammatory anaemia or functional iron deficit [46] . Twenty patients received preoperative intravenous iron plus rHuEPO and seven received only intravenous iron because rHuEPO therapy was ruled out due to cardiovascular or thromboembolic disease or because they had pure iron deficiency. There were no differences in preoperative Hb increase (1·7 g/dl) or postoperative transfusion rate between groups [46] . Although no comparison was made with oral iron, these data suggest that intravenous iron therapy may be useful improved the preoperative Hb levels in this patient population, whereas the addition of rHuEPO should be reserved for those not responding to intravenous iron.
More recently, immediate perioperative administration of iron sucrose (2 × 200 mg, days 0 and 2) plus one dose of rHuEPO (40 000 IU subcutaneously on day 0, only for patients with preoperative Hb < 13 g/dl) was evaluated in 312 patients undergoing surgery for total knee replacement (TKR) who were managed with a restrictive transfusion protocol. Again, no adverse effects of iron sucrose or rHuEPO administration were observed, and only 4% of the patients received ABT [47] . Interestingly, the ABT rate in patients with preoperative Hb < 13 g/dl (9%) was not different from that reported with the administration of 4 × 40 000 IU rHuEPO (10·8%) [48] . In addition, FDA alerted that the preliminary results of a 681 patient, multicentre, randomized, open-label study of rHuEPO (4 × 40 000 IU) compared with the standard of care orthopedic surgery showed that frequency of deep venous thrombosis in patients treated with rHuEPO was more than twice that of patients who received usual blood conservation care (4·7% vs. 2·1%, respectively) [39] .
Regarding postoperative anaemia, the administration of oral iron after orthopaedic surgery does not appear to be worthwhile [49] [50] [51] . However, iron sucrose has also been shown to be more effective in restoring postoperative Hb levels after spinal surgery in children (3 mg/kg/day) with respect to an historical control receiving oral iron [52] , whereas postoperative iron sucrose reduced the requirements for ABT in hip arthroplasty [53] . In contrast, Karkouti et al. [54] conducted a double-blinded, placebo-controlled randomized study of 31 adult patients without preoperative anaemia (13 cardiac surgery, 18 orthopaedic surgery), whose Hb was 7-9 g/dl on the first postoperative day (POD 1). Patients were assigned to one of three groups: control, intravenous iron alone (200 mg of iron sucrose on POD 1, 2 and 3) or in combination with rHuEPO (600 U/kg on POD 1 and 3). There were no between-group differences in Hb at week 1 or 6 after surgery, although higher reticulocyte counts were observed on POD 7 in the combination group. The authors concluded that early postoperative treatment with intravenous iron alone or in combination with rHuEPO does not appear to accelerate early recovery from postoperative anaemia. However, this study has several limitations, including the small number of patients recruited relative to the number of patients screened (which limits the generalizability of the results), the inclusion of cardiac and orthopaedic surgical patients (whose postoperative inflammatory reactions are quite different in intensity and duration), and the lack of parameters of baseline iron status. In addition, the authors recognized that this study cannot exclude the possibility that higher doses or different timing of postoperative intravenous iron and rHuEPO may be effective in accelerating correction of postoperative anaemia [54] .
In this regard, it has been reported that 71% of Hb loss and 92% of preoperative Hb was recovered at POD 30 in TKR patients receiving perioperative intravenous iron (2 × 200 mg, days 0 and 2) with (n = 19) or without EPO (n = 129), and only 15% of them remained anaemic [55] . This Hb reconstitution was attained without a reduction of iron stores, whereas a similar Hb reconstitution (80%) was found using oral iron or no treatment, however, at POD 56 and associated with significant reduction of ferritin levels in patients that were not transfused [56] . Hence, perioperative intravenous iron administration may hasten the recovery from postoperative anaemia and preserves iron stores in TKR patients, especially in patients with preoperative ferritin < 100 ng/ml [55] . A tentative algorithm of perioperative iron administration in patients undergoing major orthopaedic surgery is depicted in Fig. 2 .
Cardiac surgery
In the postoperative period, the administration of oral iron after uncomplicated coronary artery bypass surgery did not help to restore red blood cell mass nor to maintain total body iron stores [57] . In contrast, postoperative intravenous iron preserved iron stores during recovery from anaemia [58] . Moreover, the increase in Hb level from POD 4 (nadir) to POD 30 was 1 g/dl higher in patients who received intravenous iron supplements, with or without rHuEPO, when compared to those who received placebo [58] . However, as mentioned above, the study by Karkouti et al. [54] did not find any benefit of postoperative intravenous iron and rHuEPO in cardiac surgery [54] . Finally, a retrospective study of 863 cardiac surgery patients showed no differences in infection rates between patients receiving intravenous iron plus rHuEPO (n = 302) or ABT (n = 561), as indicated, for correction of postoperative anaemia [59] .
In adult patients scheduled for cardiac surgery, perioperative treatment with EPO reduced the risk of exposure to ABT (60/ 195, 31% vs. 56/104, 54%) [RR, 0·57; 95% confidence interval (CI), 0·43-0·75; P < 0·001], but there was a great variability in total rHuEPO dose, and there is not definitive evidence that intravenous iron is superior to oral iron in supporting rHuEPO treatment for cardiac surgery [60] .
Colorectal cancer
Iron deficiency and anaemia are frequent in colorectal cancer (CRC) patients, and they use to be related to patient's age, tumour site (right colon) and tumour size (large size), but not to clinical stage or histological type, which were significant factors related to anaemia. Thus, both IDA and iron deficiency might be therapeutic targets in CRC patients.
Oral iron supplementation (sodium ferrous citrate, 200 mg/day) to CRC patients resulted in higher Hb levels immediately before surgery, and fewer patients receiving intraoperative ABT (9·4% vs. 27·4%, P < 0·05), when compared to a control group [61] . However, there were no significant differences in postoperative Hb levels or transfusion volumes between the two groups [61] . In another study, 43 CRC patients received preoperative treatment with oral iron, if Hb > 14 g/dl, and iron deficiency; iron sucrose (200 mg/week) if Hb 10-14 g/dl; or iron sucrose (200 mg twice a week) if Hb < 10 g/dl, during 2-3 weeks. Seventeen of these patients also received postoperative iron sucrose (200 mg on days 0, 2 and 4). A retrospective series of patients not receiving iron was used as a control group (n = 66). Despite a lower baseline Hb (12·3 vs. 11·5 g/dl; P < 0·05), iron therapy reduced the transfusion index (4·0 vs. 1·3 unit/patient; P < 0·05) and the percentage of patients who received preoperative ABT (33% vs. 9%; P < 0·05), but not the percentage of patients administered perioperative ABT (48% vs. 35%; P = 0·161). However, the treatment was ineffective in patients with a high transfusion index (> 5 units/patient) [62] .
Most probably, the effectiveness of perioperative intravenous iron treatment could be enhanced by concomitant rHuEPO administration. Thus, perioperative treatment with rHuEPO reduced the risk of exposure to ABT in patients with moderate anaemia scheduled for CRC (38% vs. 47%; RR, 0·81; 95% CI, 0·61-1·00; P = 0·054), although a reduction of both the percentage of transfused patients and the number of transfused units was only observed for those receiving rHuEPO plus intravenous iron. Additionally, the use of intravenous iron allowed for a significant reduction in the total dose of rHuEPO [62] . Nevertheless, even when this is a short-term therapy, the above-mentioned uncertain role of rHuEPO administration on cancer patient's outcome should also be taken into account for this patient population. 
Gynaecological surgery
In gynaecological practice, the greatest number of blood transfusion occurs at the time of radical surgery. As many of these patients presented with IDA or iron deficiency, due to chronic blood loss, preoperative correction of anaemia emerges as a possible alternative to ABT. In two randomizedcontrolled studies including 81 healthy, mildly anaemic women who underwent total hysterectomy, patients who received rHuEPO once weekly for 3-4 weeks, plus oral iron supplementation had a significantly higher preoperative Hb levels and lower requirements for ABT than those who received only oral iron supplementation [63, 64] . However, in one of these studies, the authors found that in most cases iron only seemed to be as efficacious as iron plust rHuEPO in correcting anaemia in myoma patients preoperatively [63] . On the other hand, the efficacy and safety of treatment with intravenous iron for postoperative anaemia was prospectively assessed 52 gynaecological surgery patients (46% abdominal hysterectomy; 21% myomectomy) with Hb levels less than 10 g/dl, who received 3 × 200 mg doses of intravenous iron sucrose administered on consecutive days. Fifteen days after the last dose Hb was increased by 2·7 g/dl (95% CI 2·2-3·1; P < 0·001), only one patient had side-effects (pain at the injection site), and no patient received ABT [65] . Therefore, the low incidence of serious side-effects and the rapid recovery of Hb levels make iron sucrose a safe, effective drug for treating perioperative anaemia in this patient population.
Critically ill patients
It is well-known that more than one-third of intensive care unit patients present FID, a condition that cannot be corrected with oral iron supplements [42, 66] . Patients with FID have longer duration of episodes of systemic inflammatory response syndrome (SIRS) and longer ICU stays compared to patients without FID [66] . In contrast, anaemic critically ill patients treated with intravenous iron sucrose (20 mg/day) experienced an improvement of systemic inflammatory response (reduction of C-reactive protein levels) and a trend towards reduced transfusion and mortality rates, when compared to those in a control group who only received folic acid [67] . In a recent study, the cumulative number of red blood cell units transfused and the percentage of transfused patients were significantly lower in intensive care unit patients receiving intravenous iron sucrose (100 mg three times a week) and subcutaneous rHuEPO (40 000 units once per week or three times per week) than in patients receiving iron sucrose alone, although there were no significant differences in morbid/mortality rates among the three groups [68] (Table 4) . However, this protocol resulted in both a lower transfusion rate and a net increase in Hb levels, when compared to data reported by Corwin et al. [69] (Table 4) . Thus, the systematic administration of intravenous iron to critically ill patients seems to safe and effective in improving the dose-dependent response to rHuEPO. However, it is currently unclear whether the administration of rHuEPO to intensive care unit patients is associated with improved outcome, indicating that adequate patient selection and refined rHuEPO and intravenous iron titrations are needed in order to improve morbidity, mortality and cost-effectiveness rates.
Conclusions
Anaemia is a common condition among the patients admitted to hospital medicosurgical department, as well as in critically ill patients. Anaemia is more frequently due to absolute iron deficiency or FID (Table 1) , with other causes been less Transfusion index (U per patient)
Mortality 18·4 17·1 14·6 9·8 20·4 a rHuEPO 40 000 IU once a week, oral iron (intravenous iron if intolerance to oral iron or development of iron deficiency), transfusion threshold Hb < 9 g/dl.
b rHuEPO 40 000 IU once a week (rHuEPO-1) or three times a week (rHuEPO-2), intravenous iron sucrose 100 mg three times a week, transfusion threshold Hb < 7 g/dl. frequent. In contrast, postoperative anaemia is mainly caused by perioperative blood loss, and it might be aggravated by inflammation-induced blunted erythropoiesis. All these mechanisms may be involved in the anaemia of the critically ill patients. Patients at risk of receiving perioperative transfusions should be identified, on the basis of patient's red blood cell mass, the transfusion trigger and the expected blood loss (e.g. using Mercuriali's algorithm) [70] . Therefore, whenever clinically feasible, patients undergoing elective surgery with a high risk of severe postoperative anaemia should have Hb level [71] and iron status (serum iron, ferritin and transferrin saturation index) tested a minimum of 30 days before the scheduled surgical procedure. For patients older than 60 years, vitamin B12 and folic acid should also be measured [72] . Unexplained anaemia should always be considered as secondary to some other process and therefore elective surgery should be deferred until an appropriate diagnosis is made [71] .
Intravenous iron administration, with or without rHuEPO, to medicosurgical patients surgery seems to be safe, as very few severe side-effects were observed, and may result in lower transfusion requirements, shorter length of hospital stay and hastened recovery of anaemia. However, it is noteworthy that many of the recommendations given for intravenous iron treatment are not supported by a high level of evidence (Table 5 ) and this must be borne in mind when making decisions regarding its application to a particular patient. Nonetheless, this also indicates the need for further large, randomized-controlled trials on the safety, efficacy and cost-effectiveness of intravenous iron for treating anaemia in the clinical settings reviewed. Table 5 Grade of recommendation of intravenous iron therapy for treating anaemia and/or avoid allogeneic transfusion medicosurgical patients, according to modified Delphi methodology ( 
